sBCMA在初诊多发性骨髓瘤患者中的表达水平及其与预后的关系

Expression of sBCMA in Newly Diagnosed Multiple Myeloma Patients and Its Relationship with Prognosis

目的:研究可溶性B细胞成熟抗原(sBCMA)在多发性骨髓瘤(MM)患者外周血中的表达水平,并探讨其与MM患者预后的相关性。方法:收集31例初诊MM患者和30例健康志愿者的外周血,采用酶联免疫吸附试验(ELISA)法检测外周血中的sBCMA水平,并分析sBCMA水平与MM患者预后的相关性。结果:初诊MM患者外周血中sBCMA水平较健康对照组显著升高(P<0.05)。sBCMA水平与骨髓中浆细胞比例、M蛋白水平及治疗密切相关(P<0.05)。sBCMA水平与MM患者总生存期(OS)呈负相关(r=-0.47),sBCMA低表达的MM患者较sBCMA高表达患者OS显著延长(P<0.05)。结论:sBCMA在MM患者中显著升高,有望作为评估MM患者疗效以及预后的一种新指标。通过靶向sBCMA,可能为MM的治疗提供新的思路。

Objective:To study the expression level of serum B-cell maturation antigen(sBCMA)in the peripheral blood of newly diagnosed multiple myeloma(MM)patients,and explore its relationship with the prognosis of MM patients.Methods:The peripheral blood of 31 newly diagnosed MM patients and 30 healthy volunteers were collected.The level of sBCMA in the peripheral blood was detected by enzyme-linked immunosorbent assay(ELISA).The correlation between the level of sBCMA and the prognosis of MM patients was analyzed.Results:The level of sBCMA in newly diagnosed MM patients was significantly higher than that in healthy controls(P<0.05).The level of sBCMA was closely related to the plasma cells ratio in bone marrow,the M protein level and the treatment(P<0.05).The level of sBCMA was negatively correlated with the overall survival(OS)of MM patients(r=-0.47).MM patients with low expression of sBCMA had significantly longer OS than patients with high expression of sBCMA(P<0.05).Conclusion:The level of sBCMA is significantly increased in MM patients,which is expected to be a new indicator for evaluating the curative efficacy and prognosis of MM patients.Targeting sBCMA may provide new ideas for the treatment of MM.